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ACETIC acid induced colitis in rats was used to investigate
the effects of malotilate, a drug which has been shown to
inhibit 5-1ipoxygenase in human macrophages, the
malotilate derivate ZY16268 and the flavenoid ZY16369 on
the eicosanoid production and the colonic morphology in
inflammatory bowel disease. Acetic acid produced an
acute inflammatory response in the colon, associated with
a markedly raised inflammation score (15.8 vs. < 0.5),
based on a seven-scaled scoring system which includes
observation of haemorrhage, submucosal oedema, cellular
infiltration, goblet cell depletion, loss of architecture, crypt
abscesses and serosal involvement, of which every item
was subdivided as mild, moderate and severe. Incubation
of colonic mucosa from rats treated with arachidonic acid
and stimulated with A23187 showed an increase of the
cyclooxygenase product 12-hydroxy-heptadecatrienoic
acid (HHT) and the 12-1ipoxygenase product (12-HETE)
and a decrease in the formation of 6-keto-prostaglandin
FI(6kPGFI) in comparison with normal rat mucosa.
Malotilate, ZY16268 and ZY16369 all resulted in a decrease
in HHT, leukotriene B (LTB4)-like compounds and
12-hydroxyeicosaenoic acid (12-HETE) production. None
of the tested compounds significantly reduced the colonic
damage by acetic acid although the formation of12-HETE
was proportional to the histologically obtained inflamma-
tion score. There were marked differences in eicosanoid
formation patterns between rat and human mucosa, both
normal and inflamed. In view of the hyperacute nature of
the mucosal damage and the marked differences in
eicosanoid production, acetic acid induced colitis in rats
is probably not a suitable model of ulcerative colitis in
humans.
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Introduction
Acetic acid (HAc) colitis in rats is an
experimental model of acute colitis which shares
many of the histological features of ulcerative colitis
such as mucosal oedema, ulceration and infiltration
of the mucosa by neutrophils. In contrast to
ulcerative colitis which histologically is a mixture
of both acute and chronic inflammation, acetic acid
colitis is a pure acute inflammation. The pattern of
arachidonate metabolism in HAc colitis has been
reported to be similar to that in human ulcerative
colitis.
5-Lipoxygenase products have been proposed as
major inflammatory mediators in bowel disease and
in particular in ulcerative colitis. 1’2 In inflammatory
bowel disease (IBD) the synthesis of leukotriene B4
(LTB4) is indeed increased in inflamed mucosa.
3-6
Drugs which inhibit leukotriene synthesis, such as
5-aminosalicylic acid and prednisolone, have been
shown to reduce inflammation in several animal
(C) 1993 Rapid Communications of Oxford Ltd
models of IBD, including acute and chronic models
in rats, rabbits and mice. In most of these studies
measurements of eicosanoids were limited to LTB4
and prostaglandin E2 (PGE2).
Apart from leukotrienes, other lipoxygenase and
cyclooxygenase products are formed in inflamed
tissue. Studies in which the metabolism of
exogenous AA by colonic mucosa in IBD was
investigated showed a three- to five-fold increase of
other eicosanoids, including 12- and 15-HETE and
HHT. Mono-HETEs have been shown to act
as stimulators of mucus secretion and have
inflammatory effects in the skin.
2
Malotilate is a compound which has been
reported to be effective in reducing liver damage
and fibrosis in experimental liver disease and in
patients with chronic hepatitis and cirrhosis.
13 It has
previously been shown that malotilate inhibits
lipoxygenase activity in human macrophages.
4 The
suppression of 5-1ipoxygenase by malotilate sug-
gested that this or similar compounds might be
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effective anti-inflammatory agents in IBD. The
authors therefore decided to study the effects of
malotilate, the compound ZY 16268 (a derivate of
malotilate) and ZY 16369 (a flavenoid), given
systemically, in rats with HAc induced colitis.
Eicosanoid synthesis in rat colonic tissue of
controls, of non-treated rats with HAc colitis and
of rats with HAc colitis treated with single
compounds were measured. Samples were taken
throughout the colon, in ascending, high sigmoid
and rectum, in order to determine the predominant
eicosanoids in HAc colitis, to investigate the eects
of the three compounds on the eicosanoid
production and to determine whether treatment
with these compounds leads to a reduction in
inflammation. In addition, it was decided to
compare eicosanoid formation in HAc-induced
colitis in rats with that found in human ulcerative
proctocolitis, by examining eicosanoid formation in
biopsies taken from patients undergoing diagnostic
sigmoidoscopy or colonoscopy.
Materials and Methods
Materials: Malotilate, ZY 16268 and ZY 16369
were provided by ZYMA, Switzerland. In view
of the known difficulty in dissolving the com-
pounds, it was decided to use polyethyleneglycol
(PEG) 400 as the vehicle for administering the
drugs intraperitoneally. Drugs were given at a high
dose level (100 mg/kg/day) in an attempt to ensure
adequate tissue levels.
Experimental colitis: 25 Wistar rats (Hope Farms)
weighing 200 g were fasted for 36 h and then
anaesthetized with ether. A midline abdominal
incision was made and the junction of the coecum
and ascending colon identified and ligated. Two
millilitres of 5% HAc was injected into the lumen
of the ascending colon through a 25 gauge needle,
and this was followed immediately by an injection
of 4 ml of air to clear the colon of most of the acetic
acid. The incision was closed. Twenty-four hours
later the rats were killed and the colons isolated.
Segments approximately 5 mm long were taken for
histology and for analysis of eicosanoid production
from three sites--one just distal to the site of
injection (ascendens), one close to the rectum and
one midway in the colon (descendens).
divided into five groups: Rats were
Group Pre-treatment Colon lavage
1 PEG 400 0.9% (w/v) NaCl
2 PEG 400 5.0% (w/v) HAc
3 Malotilate 5.0% (w/v) HAc
4 ZY 16268 5.0% (w/v) HAc
5 ZY 16369 5.0% (w/v) HAc
Malotilate, ZY 16268 and ZY 16369 were dissolved
in PEG 400 and given in a dose of 100 mg/kg/day
intraperitoneally for 4 days (the third administration
20 h after lavage of the colon with HAc and the last
administration I h before the rats were killed). PEG
400 only was administered in a similar fashion to
groups 1 and 2.
Patients: Patients fulfilling the following entry
criteria were candidates for the study: (a) proven
ulcerative colitis localized in the sigmoid and/or the
rectum; and (b) who had no drug treatment for at
least a month prior to the colonoscopy. The group
consisted of eleven patients (eight men, three
women, aged 21-64 years). As controls 13 patients
(six men, seven women, aged 22-72 years) were
taken, from whom any kind of IBD was excluded.
Three biopsies were used for measurements of
eicosanoid synthesis.
Incubation conditions: Segments of colon were weighed,
minced and homogenized in 2.5 ml Krebs-Hense-
leit buffer pH 7.4 with an Ultra-Turrax homo-
genizer for 10 s on melting ice. Total protein
content was determined by the Lowry method.
Each sample was incubated with 0.125 #Ci
[1-14C]-archidonic acid together with 1/M calcium
ionophore A23187 (Sigma, USA) at 37C for 15 min
while shaking. After this, 3H-labelled compounds
(6kPGFI, PGF2, PGE2, TxB2, LTB4, 15-HETE,
12-HETE and 5-HETE) were added as chromato-
graphic standards and for recovery purposes (all
labelled compounds were from Amersham, UK).
Samples were centrifuged for 2 min at 16 000 x
at 4C. The supernatant was applied to a Sep Pak
Cs cartridge (Waters Ass., USA), eluted with
methanol and dried with a Savant Speed Vac
concentrator. The pellet was dissolved in 250/1
methanol and filtered through an Anatop 0.2 zm
filter into an HPLC polypropylene microvial. One
hundred microlitres of this was injected onto two
combined Nucleosil 5C8 HPLC columns (3 x
200 mm, Chrompack, The Netherlands). HPLC was
performed with a Hewlett Packard 1048B liquid
chromatograph with variable wavelength detector.
Radioactivity was measured on-line with a Berthold
LB506C monitor. The solvent system contained a
gradient of 0.12% trifluoracetic acid and 0.2%
triethylamine in water (pH 3.0) and acetonitrile
(LichrsolvR, Merck, Germany). The flow rate was
0.5 ml/min at 37C.
5
Histological studies: Representative cross-sections,
taken from the rat colon at 1, 6 and 12 cm dista.1 to
the coecal-ascending colon junction, were fixed in
4% buffered formaldehyde. Histological examina-
tions were performed with haematoxylin and
azafloxin stained cross-sections of the colons. The
severity of colitis was graded by a seven-scaled
scoring system which includes observation of
haemorrhage, submucosal oedema, cellular infiltra-
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tion, goblet cell depletion, loss of architecture, crypt
abscesses and serosal involvement, of which every
item was scored as mild, moderate and severe.
Therefore, there was a minimum histological grade
of 0 and a maximum grade of 21.
Statistical analysis" Data are reported as the
mean-+-S.E.M, of the combined experiments.
Differences were analyzed for significance using
Student’s two tailed t test, the Wilcoxon’s test for
paired variates and the Duncan’s multiple range
test. Values ofp < 0.05 were considered significant.
Results
Weight" The mean wet weight of the sections of all
the groups were" in the ascendens, 161 + 9 mg;
in the descendens, 131_+8mg; and in the
rectum, 109 __+ 5 mg. Protein content was increased
in the descendens and the rectum in comparison
with the ascending colon (ascendens 60 3/g/mg,
descendens 67 -+- 3/2g/mg, rectum 73 __+ 3/2g/mg).
Eicosanoidformation" The pattern of the most common
eicosanoids formed by rat rectal colonic tissue are
shown in Fig. la, and the eicosanoid formation
by human rectal mucosa is given in Fig. lb. The
pattern of eicosanoids produced by rat colonic
tissue, after incubation with 14C-AA and stimulation
by A23187 differs from that produced by humans.
In rats the main metabolites of AA are 6kPGFI
(48.4%), 12-HETE (15.5%) and HHT (17.5%),
whereas the main products of human rectal mucosa
are 15-HETE (32.0%), HHT (18.6%), TxB2 (12.0%)
and PGE2 (10.8%).
Induction of an acute colitis in rats with HAc
results in a significant increase in 12-HETE (32.9%)
formation and a significant decrease in the
formation of 6kPGFI (22.1%). In ulcerative colitis
in men only 15-HETE was significantly increased.
In both humans and rats, LTB4-1ike compounds
represent a minor part of the AA metabolism.
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FIG. 1. (a) Formation of the most common eicosanoids of rat rectal
mucosa, after either saline (mean total formation 8100dpm/100/g
protein) or acetic acid treatment (mean total formation 24870 dpm/100
/g protein); and (b) of non-inflamed (mean total formation 6890 dpm/
100/g protein) and inflamed (mean total 7990 dpm/100/g protein)
human mucosa, expressed as percentage of total formation (*p < 0.05 vs.
controls).
Significant changes in the individual eicosanoids
following drug treatment were only seen in the
rectum. In Table 1 the formation of some
eicosanoids by rectal tissue is given for malotilate
and the compounds ZY 16268 and ZY 16369 in
comparison with the non-treated HAc induced
colitis. Table I shows that malotilate, ZY 16268 and
ZY 16369 all resulted in a decrease in the HHT,
Table Formation of eicosanoids by rat rectal colonic tissue vs. treatment with or
without different compounds (expressed as dpm/100/g protein)
Eicosanoids formed
Group
(n 5) 6kPGFI= LTB4 HHT 12-HETE
Control 3240 4- 980 910 4- 240 1160 4- 100 2350 4- 470
Non-treated 5720 + 2220 1600 _+ 340* 4170 _+ 380* 7500 4- 1760*
HAc colitis
Malotilate 5460 4- 190 720 _+ 330** 1540 _+ 140** 3250 _+ 370**
HAc colitis
ZY 16268 5610 _+ 1120 680 4- 100"* 2760 -I- 540** 4060 4- 470**
HAc colitis
ZY 16369 6390 4- 940 580 _+ 70** 2810 4- 210"* 5440 4- 590
HAc colitis
p < 0.05 vs. controls.
p < 0.05 vs. non-treated HAc colitis.
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Table 2. Mean inflammation
score after treatment with HAc,
malotilate, ZY 16268 and ZY
16369
Group Score
(n=5)
Control <0.5
Non-treated 15.8 + 1.9
HAc colitis
Malotilate 14.7 + 2.8
HAc colitis
ZY 16268 17.2 + 1.2
HAc colitis
ZY 16369 13.8 + 2.1
HAc colitis
LTB4 and 12-HETE production. The three
compounds inhibit both the 5- and 12-1ipoxygenase
products and HHT.
In)qammation score: HAc produced a marked in-
flammatory response in the mucosa and the
submucosa colon, associated with a significantly
raised inflammation score (mean 15.8 vs. < 0.5).
Although the formation of the 5- and 12-
lipoxygenase products was significantly inhibited,
none of the tested compounds had significant effect
on the inflammation score. The compound ZY
16268 resulted in a slight increase in inflammation
score (17.2 vs. 15.8) (Table 2). The 12-HETE
production showed a significant correlation (rs:
0.58; p <0.01) with the inflammation scores
(Fig. 2).
Discussion
The present study was undertaken to investigate
the effect of malotilate, its derivate ZY 16268 and
flavenoid ZY 16369 on the eicosanoid production
in a rat model of acute colonic inflammation. It was
decided to use the model acetic acid induced colitis
in rats, because of the expected similarity of the
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FIG. 2. Inflammation score vs. 12-HETE production (dpm/100#g
protein) by rat rectal colonic tissue (n 22, p < 0.01, 0.58).
pattern of arachidonate metabolism to human IBD.
This rat model provoked a severe inflammation of
the colon, in which a mean of 80% of the maximal
inflammation score was reached. In the normal
colonic mucosa of rats, relatively hi_gh amounts of
6kPGFI, HHT and 12-HETE were formed.
Previous experiments have shown that 5-HETE is
also one of the prominent products.
After induction of the inflammation, total
eicosanoid production was dramatically increased,
although the relative formation did not change
significantly. In HAc colitis mucosa a significant
increase of LTB4, HHT and 12-HETE compared
to normal rat mucosa was observed. In inflamed
colonic mucosa of patients with active ulcerative
colitis, the synthesis of leukotrienes, products of
5-1ipoxygenase metabolism and prostaglandins
(PGs), products of the cyclooxygenase metabolism
are enhanced, compared to normal tissue.>3’6
Recently, the authors have shown that the
15-1ipoxygenase product 15-HETE is the main
eicosanoid formed by human colonic mucosa and
that this metabolite ofAA is increased significantly
in inflamed human colonic mucosa.
7
The results of this study indicate that the pattern
of eicosanoid formation in HAc induced colitis in
rats differs from those seen in human IBD. This is
in agreement with our previous findings in which
marked species differences in the pattern of
eicosanoid formation by macrophages were ob-
served.
18
The only AA metabolite positively correlated
with the inflammation score was 12-HETE. The
same was observed with 15-HETE in a human IBD
study.
17 The functions of 12- and 15-HETE in
inflamed colonic mucosa is not clear. In blood
platelets, the major AA metabolites are TxB2, HHT
and 12-HETE,
9 the same eicosanoids that are
increased in acetic acid colitis mucosa. Macrophages
mainly form LTB4 and 5-HETE,
4 whereas
endothelial cells generate PGI2 (prostacyclin) and
15-HETE. It is possible that whether endothelial
cells in the colonic mucosa synthesize either PGI2
(measured as 6-keto-PGF) or 15-HETE is species
dependent. Furthermore the origin of these ceils
(alveoli, liver, kidney or colon) could restrict the
differential synthesis of eicosanoids.
Histological examination of the rectal and
sigmoidal colonic tissues showed a number of
haemorrhages, which suggests the participation of
platelets and endothelial cells in both the
inflammation and the eicosanoid formation (Fig.
3). The present investigations showed that
treatment with malotilate, ZY 16268 or zY 16369
resulted in a significant decrease of the production
ofHHT and LTB4. Both malotilate and its derivate
ZY 16268 gave a significant reduction in the
formation of 12-HETE. The effects of the three
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(a)
FIG. 3. Histological sections of rectal colonic mucosa. Tissue samples
were taken and fixed immediately after sacrifice. (a) Section from a
control rat--no histological detectable damage was observed; (b)
sections of rectum after non-treated acetic acid; and (c) ZY 16369 treated
acetic acid showing cell infiltration (A), goblet cell depletion (B), loss of
architecture (C) and areas of haemorrhages (D). 250).
drugs on eicosanoid production are similar to those
previously reported with human peritoneal macro-
phages, with the exception of malotilate which
showed an increase of the 12-HETE production,
human macrophages, possibly due to a positive
feedback mechanism.
2
In ulcerative colitis the initial event is followed
by a secondary reaction, in which inflammatory cells
secrete mediators, with both beneficial and harmful
effects. From our investigations it is clear that,
although the formation of mediators of inflamma-
tion was successfully inhibited, the degree of
inflammation did not improve. This unexpected and
contradictory finding could be due to: (i) Mediators
of inflammation such as eicosanoids do not play an
important role in the initial phase of the
inflammation. Recent evidence suggests a key role
of cytokines and platelet activating factor (PAF)
21
in the initial stages, whereas eicosanoids could be
important regulators during the later (chronic)
inflammation. (ii) This type of experimental colitis
is too acute (<24h) for a major role for
inflammatory ceils, which are characteristic of later
stages of inflammation. The evidence for this is the
low number of leucocytes and macrophages, the
main donors for eicosanoid production. A subacute
model for colitis, such as the dextran sodium
sulphate (DSS) mouse model or the TNBS
(2,4,4-trinitrobenzene sulphonic acid) rat model
22
would probably be a better choice to observe the
effects of potent 5-1ipoxygenase synthesis inhibitors
on in vivo inflammation.
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